Floatz logo

Revusiran

TTR-mediated Amyloidosis

Alnylam Pharmaceuticalsnucleic_acidPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the TTR-mediated Amyloidosis cohort.

Asset / SponsorPhaseRating
Patisiran
Alnylam Pharmaceuticals
Phase 3A
Patisiran
Alnylam Pharmaceuticals
Phase 3BB
Patisiran
Alnylam Pharmaceuticals
Phase 3BB
Revusiran
Alnylam Pharmaceuticals
Phase 3BB
Aln-Ttrsc02
Alnylam Pharmaceuticals
Phase 3BB

View all 12 →

Same molecule, other indications

Revusiran is also rated in:

familial amyloid neuropathyDormant
BB
Indicative ·
69 / 100
View asset →
Amyloid NeuropathiesDormant
BB
Indicative ·
69 / 100
View asset →
hereditary amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →